Michael Curran

17PUBLICATIONS
200CO-AUTHORS
Predictive and prognostic markersMolecular medicineGene and molecular therapyImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Nov 02, 2026
RhoA Y42C drives cell plasticity and PD-1-mediated immune evasion of diffuse gastric cancer.

|Apr 14, 2026
Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.

Ahmad Salameh, Elisabetta Bolli, Manuela Iezzi

|Feb 12, 2026
STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.

Mark W Youngblood, Shashwat Tripathi, Hinda Najem

|May 16, 2025
NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma.

Spencer T Lea, Chao-Hsien Chen, Jun Wei

|Apr 18, 2025
Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.

Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang

|Oct 30, 2024
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma.

Ricardo DeAzevedo, Madeline Steiner, Broderick X Turner

Pageof 3

Frequent Collaborators

3 joint publications

Chunru Lin

3 joint publications

Zilong Zhao

3 joint publications

Jaffer A Ajani

3 joint publications

Mien-Chie Hung